Jove
Visualize
Contact Us

Related Experiment Videos

Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.

Christian M Kurbacher1, Ian A Cree

  • 1Department of Gynecology and Obstertrics, University of Cologne, Cologne, Germany.

Methods in Molecular Medicine
|May 20, 2005
PubMed
Summary

The microplate adenosine triphosphate (ATP)-based tumor chemosensitivity assay (ATP-TCA) offers a reliable method for predicting chemotherapy effectiveness in various cancers. This validated assay improves treatment outcomes, showing over 90% accuracy in breast and ovarian cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for histopathology.

Histopathology·2026
Same author

The International Classification of Diseases for Oncology, 4th Edition (ICD-O-4): An overview.

Cancer epidemiology·2026
Same author

Tumour markers and evidence-based pathology.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2026
Same author

Development of a decision tree diagram for classifying study designs in tumour pathology research: a multidisciplinary approach.

The journal of pathology. Clinical research·2025
Same author

The World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Part 2 - Spleen and Thymus.

Acta cytologica·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Biotechnology
  • Clinical Diagnostics

Background:

  • Traditional chemosensitivity assays faced limitations in standardization, reproducibility, and efficacy.
  • Novel nonclonogenic methods have emerged to address these challenges in pretherapeutic testing.

Purpose of the Study:

  • To evaluate the microplate adenosine triphosphate (ATP)-based tumor chemosensitivity assay (ATP-TCA) for ex vivo chemosensitivity testing.
  • To highlight the clinical and preclinical experience with ATP-TCA in various solid tumors.

Main Methods:

  • The ATP-TCA utilizes a microplate format to assess tumor cell viability after drug exposure.
  • Requires minimal tumor cells (1 x 10^6) for testing multiple drugs or combinations.
  • Commercially available kit with a standardized, reproducible technique.

Related Experiment Videos

Main Results:

  • ATP-TCA demonstrates high predictive accuracy (>90%) for ovarian and breast carcinomas.
  • Achieves high positive (85-90%) and negative (near 100%) predictive values.
  • Prospective trials showed ATP-TCA-selected chemotherapy tripled response rates and doubled survival in ovarian cancer patients.

Conclusions:

  • ATP-TCA is a well-documented and validated technology for nonhematological tumor chemosensitivity testing.
  • The assay accurately predicts clinical response and survival, aiding in personalized cancer treatment.
  • ATP-TCA is valuable for new agent development and screening novel chemotherapy regimens.